Arvinas to Participate in Upcoming Investor Conferences
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5.
Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.
Details
News Market Reaction – ARVN
On Aug 29, the day this news came out, ARVN closed 0.39% below the previous close.
Data tracked by StockTitan Argus for the Aug 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:
- Wells Fargo Healthcare Conference on Thursday, September 4. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
- Cantor Global Healthcare Conference on Friday, September 5. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.